LUME-Ovar 1: Nintedanib (BIBF 1120) or Placebo in Combination With Paclitaxel and Carboplatin in First Line Treatment of Ovarian Cancer

NCT01015118 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1366

Enrollment

INDUSTRY

Sponsor class

Conditions

Ovarian Neoplasms
Peritoneal Neoplasms

Interventions

DRUG: Placebo
DRUG: Paclitaxel
DRUG: BIBF 1120
DRUG: Carboplatin
DRUG: Paclitaxel
DRUG: Carboplatin

Sponsor

Boehringer Ingelheim